StoxPine Labs vs CreditAccess Grameen: share price & financials comparison
NSE: PINELABS vs CREDITACC · Financial Services · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Pine Labs vs CreditAccess Grameen at a glance
Pine Labs (PINELABS) has a market capitalisation of ₹18,758 Cr, against ₹17,386 Cr for CreditAccess Grameen (CREDITACC). Pine Labs comes out ahead on technicals. CreditAccess Grameen comes out ahead on growth. Across the scored metrics below, Pine Labs leads on 2 and CreditAccess Grameen on 2. On StoxGud's 10-point checklist, Pine Labs scores 3/10 and CreditAccess Grameen scores 1/10.
| Metric | Pine Labs | CreditAccess Grameen |
|---|---|---|
| Size | ||
| Market cap | ₹18,758 Cr | ₹17,386 Cr |
| Revenue (latest FY) | ₹2,711 Cr | ₹6,063 Cr |
| Net profit (latest FY) | ₹113 Cr | — |
| Valuation | ||
| P/E | 191.5 | — |
| P/B | 3.12 | — |
| Profitability | ||
| Return on equity | 1.6% | — |
| Net profit margin | 3.3% | — |
| Operating margin | 15.4% | — |
| Growth | ||
| Revenue growth (YoY) | +24.0% | +26.2% |
| Net profit growth (YoY) | +546.1% | — |
| Revenue CAGR (multi-year) | — | +19.7% |
| Financial health | ||
| Debt to equity | 0.03 | — |
| Momentum | ||
| 1-month return | -8.6% | -12.6% |
| 1-year return | — | -22.8% |
| 3-year CAGR | — | -13.9% |
| 5-year CAGR | — | +11.5% |
| Distance from 52W high | -35.3% | -32.9% |
| Technicals | ||
| RSI (14) | 48 | 31 |
| Price vs 200-day avg | -5.9% | -18.6% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Pine Labs | CreditAccess Grameen |
|---|---|---|
| Price above 50-day average | ✗ | ✗ |
| Price above 200-day average | ✗ | ✗ |
| 50-day average above 200-day (uptrend) | ✗ | ✗ |
| RSI in healthy 40–70 zone | ✓ | ✗ |
| Positive 1-year return | ✗ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✗ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✗ | ✗ |
| P/E below industry median | ✗ | ✗ |
| Score | 3/10 | 1/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Pine Labs or CreditAccess Grameen?
Pine Labs has a market cap of ₹18,758 Cr and CreditAccess Grameen has a market cap of ₹17,386 Cr as of 06 Nov 2026.
Is Pine Labs or CreditAccess Grameen a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Pine Labs scores 3/10 and CreditAccess Grameen scores 1/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.